The most complete network!

This issue of R&D data analysis has conducted an in-depth exploration of the research and development progress of global targets, and provided the R&D/BD/strategic/investment elites with the most comprehensive "New Chinese Targets" and "New Global Targets" in the entire network, and provided early warnings for needs The carefully laid out "target point of the Red Sea"

01 Which targets are brand new in China?

More than half of "China's new targets" are related to anti-tumor

We have counted researches on existing drugs in the world, but China has no targets for related drug INDs (hereinafter referred to as "China's new targets").

Among these 1541 targets, 50% are anti-tumor drug-related targets

Figure 1 Distribution of China's new target therapeutic areas

Most "Chinese new targets" are also in the early stages of global R&D

According to the statistics of the world's highest research and development stage of related drugs, most Chinese new targets are still in the early stage of the world's highest research and development stage (see Figure 2, the highest stage of 1019 target-related drugs is lower than the clinical phase I)

Figure 2 Distribution of China's new targets at the highest R&D stage in the world

There are also "niche dark horses" in the "China's new targets" that are hotter in global development.

Table 1 lists the Top20 Chinese new targets with a large number of drugs developed worldwide and hot research.

Table 1 China's new targets in the world's top 20 developed drugs

02 Which targets are new in the world?

There are many potential stocks in the "Global New Targets" to develop "sustainability"

We have counted the number of new targets (hereinafter referred to as "global new targets") that only appeared in drug development after 2011 on a global scale.

Figure 3 Development of new global targets with better "sustainability"

Among the "sustainable" "new global targets", only 4 targets have nothing to do with anti-tumor

Similar to the therapeutic field distribution of China's new targets, 27 of these 31 targets are related to anti-tumor drugs (see Figure 4.

Figure 4 Development of "sustainable" global new target therapeutic areas

Which targets are best to be laid out carefully?

We respectively counted the Top20 targets with the largest number of approved drugs developed in the world and China (see Figure 5 and Figure 6)

For these more mature targets, careful consideration should be given to R&D projects and strategic discussions

Figure 5 Top20 targets of global R&D approved drugs

Figure 6 Top20 targets of the number of approved drugs developed in China